Pharvaris (NASDAQ:PHVS) Downgraded to “Sell” Rating by Wall Street Zen

Pharvaris (NASDAQ:PHVS) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other equities analysts have also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Wednesday, December 3rd. Leerink Partners set a $38.00 target price on shares of Pharvaris in a research report on Wednesday, December 3rd. Citigroup restated a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th. Guggenheim lifted their price target on shares of Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Wedbush boosted their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.56.

Pharvaris Trading Up 1.4%

Shares of NASDAQ PHVS opened at $28.39 on Friday. The stock has a fifty day moving average price of $26.68 and a 200 day moving average price of $24.71. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.80. The company has a market cap of $1.48 billion, a P/E ratio of -8.84 and a beta of -2.79.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PHVS. General Atlantic L.P. raised its stake in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after purchasing an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC increased its holdings in Pharvaris by 8.3% in the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after buying an additional 368,000 shares during the last quarter. venBio Partners LLC increased its holdings in Pharvaris by 8.2% in the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after buying an additional 350,000 shares during the last quarter. Deerfield Management Company L.P. raised its stake in Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after buying an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP lifted its holdings in Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after buying an additional 507,043 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.